Edison Oncology and Senz Oncology Complete Enrollment in Phase 1-2a Trial of EO1001, Advancing Development in ErbB-Driven Cancers

July 30, 2026 9:00 AM

Edison Oncology Holding Corp. ("Edison Oncology" or the "Company") and Senz Oncology Pty Ltd. ("Senz Oncology") today announced the completion of enrollment in the ongoing Phase 1-2a study of EO1001, Edison Oncology's oral, brain-penetrant pan-ErbB inhibitor, following the Phase 2 expansion cohorts (described as actively enrolling at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting). The trial (ANZCTR: ACTRN12620000583943),...

Read more

IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign

July 29, 2026 8:30 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that it is evaluating potential civil remedies following the federal jury verdict in United States v. Andrew Left, No. 2:24-CR-456, in the United States District Court for the Central District of California. According to the United States Attorney's Office for the Central...

Read more

BioInvent Publication in JECCR: Tailored FcγR Blockade with BI-1206 and BI-1607 Enhances Cancer Antibody Therapies and Overcomes Resistance in Preclinical Models

July 28, 2026 2:20 AM

BioInvent International (STO:BINV)Preclinical proof-of-concept data support two distinct FcγR-blockade strategies to enhance cancer antibody therapies and overcome resistanceBI-1206 boosts αPD-1 antibody activity by protecting effector CD8+ T cells from macrophage-mediated depletion, a mechanism identified as limiting αPD-1 efficacyFindings reinforce the mechanistic rationale for BI-1206's ongoing Phase 2a evaluation with pembrolizumab in...

Read more

Full Lineage Multi-Species Primary Neural Cells Officially Launched: Cloud-Clone Establishes Core Raw Material Advantages for Neuroscience and Regenerative Medicine

July 27, 2026 10:00 AM

A long-standing industry bottleneck plagues central nervous system (CNS) drug development: approximately 92% to 96% of candidate drugs that succeed in animal studies ultimately fail human clinical trials. The poor predictive performance of traditional research models creates a costly translational gap across neuroscience research. To bridge this divide, researchers worldwide are turning to physiologically relevant in vitro models, whose...

Read more

Inside Information: Faron Announces Encouraging First Overall Survival Data from Frontline Higher-Risk (HR) MDS Patients in the BEXMAB Phase 1/2 Trial

July 27, 2026 2:15 AM

Faron Pharmaceuticals Ltd. ((HEL:FARON)(LSE:FARN), a global, clinical-stage biopharmaceutical company focused on creating innovative cancer treatments that leverage the patient's own immune system, today announced that it has conducted its first overall survival (OS) data cut from treatment-naïve higher-risk myelodysplastic syndrome (HR-MDS) patients enrolled in the BEXMAB trial. At this time, after a median follow-up of 14.9 months, the only...

Read more

Faron Pharmaceuticals Ltd: Holding(s) In Company

July 24, 2026 2:20 AM

Faron Pharmaceuticals (HEL:FARON) (LSE:FARN)Faron Pharmaceuticals Ltd | Company announcement | July 24, 2026 at 09:00:00 EESTTR-1: Standard form for notification of major holdingsNOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:Faron Pharmaceuticals OY1b. Please indicate if the...

Read more

eXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing

July 23, 2026 4:15 PM

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines, - announced it has been selected to participate in the inaugural U.S. Department of Energy (DOE) Genesis Mission, a nationwide initiative bringing together leading researchers, national laboratories and industry leaders to accelerate scientific discovery through artificial...

Read more

Notice of Extraordinary General Meeting in Alligator Bioscience AB

July 23, 2026 3:10 AM

Alligator Bioscience (STO:ATORX)The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.The shareholders of Alligator Bioscience AB, Reg. No. 556597-8201, are invited to the extraordinary general meeting to be held on Wednesday 26 August 2026 at 11.00 CEST, at Medicon Village, conference room Collaboraction, Scheelevägen 4 in Lund,...

Read more

Alligator Discontinues Independent Development of Mitazalimab for a Strategic Refocus on the HLX22 Project, Announces a Rights Issue of Units of Approximately SEK 125.6 Million and Raises Bridge Loans

July 23, 2026 2:35 AM

Alligator Bioscience (STO:ATORX) - The Board of Directors of Alligator Bioscience AB ("Alligator Bioscience" or the "Company") has resolved to discontinue further independent development of mitazalimab and to strategically refocus the Company's resources on the out-licensed HLX22 project and, in order to secure funding for the Company's continued operations, the Board of Directors has today, subject to approval by an extraordinary general...

Read more

ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026

July 21, 2026 4:05 PM

ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2026 second quarter on Monday, August 3rd, after the market close.Investors and analysts are invited to listen to the live broadcast review of the Company's 2026 second quarter on Monday, August 3rd at 4:30 p.m. Eastern...

Read more

From Polyclonal to Monoclonal Antibodies: Cloud-Clone Builds a Global Benchmark for Diverse Research Antibodies via Full In-House R&D

July 20, 2026 9:30 AM

As life science research grows more refined and diversified, antibodies are no longer mere lab tools-they have become critical determinants of research data reliability. With continuously segmented target studies and evolving experimental workflows, multifaceted research demands raise higher standards for antibody resource abundance and compatibility.For nearly two decades, Cloud-Clone has specialized in research antibody development. We...

Read more

Prolocor Announces the Publication of Two Important New Analyses from a Recently Completed Clinical Study

July 20, 2026 9:00 AM

Prolocor, Inc., a healthcare company developing the innovative diagnostic Prolocor pFCG™ test to identify patients at risk of thrombotic events, today announced the publication of two analyses from a recently completed clinical study of the pFCG test. The first, "Increased Platelet FcɣRIIa Identifies Patients at Greater Risk of Multiple Cardiovascular Events After Myocardial Infarction," was published in JACC: Advances, a journal of the American...

Read more

Regentis Receives Japanese Patent allowance, Strengthening its Global GelrinC Intellectual Property Portfolio with New Proprietary Manufacturing Technology

July 20, 2026 9:00 AM

Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, announced today that the Japan Patent Office has issued a Notice of Allowance for the Company's patent application titled "Organic Solvent Free Compositions Comprising Protein-Polymer Conjugates and Uses Thereof" for its proprietary organic solvent-free manufacturing process and...

Read more

Biovica Receives First Work Order Under Expanded Master Services Agreement with Leading Global Pharmaceutical Customer

July 20, 2026 3:20 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a company specializing in blood-based cancer monitoring, today announced that it has received the first work order under its recently expanded Master Services Agreement with a current customer, one of the world's leading pharmaceutical companies with a broad and active oncology pipeline.The work order covers DiviTum® TKa testing services for a new oncology clinical study...

Read more

First Ascent Biomedical Responds to ASCO Clarification on Functional Precision Medicine

July 17, 2026 2:00 PM

First Ascent Biomedical today welcomed ASCO's Clinical Notice clarifying the role of Functional Precision Medicine (FPM) in oncology. We applaud the guidance ASCO is providing to clinicians, regulatory entities and payors.The notice reinforces that functional assays, including ex vivo live-cell drug sensitivity testing, are decision-support tools that may help inform clinical evaluation for patients with complex, relapsed, or treatment-resistant...

Read more

BioInvent's BI-1808 Abstract from Modest to Meaningful in Platinum-Resistant Ovarian Cancer Accepted for Poster Presentation at ESMO 2026

July 17, 2026 2:15 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that its abstract describing BI-1808 in recurrent platinum-resistant ovarian cancer (PROC) has been accepted for a poster presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain.Recurrent ovarian cancer that has progressed...

Read more

LIR Life Sciences Signs Development Services Agreement with Oxygen Handel GmbH (OH) to Advance Regulatory and Preclinical Roadmap for Transdermal Obesity Pipeline

July 16, 2026 6:00 PM

LIR Life Sciences Corp. (CSE:SKNY)(OTCPK:BBCMF)(Frankfurt:N790, WKN: A41QA9) ("LIR" or the "Company") is pleased to announce that it has entered into a services agreement with Oxygen Handel GmbH ("OH"), a specialized preclinical and regulatory development organization, to initiate Phase 0 strategic development planning for the Company's transdermal metabolic therapeutics pipeline.Under the agreement, OH will conduct an FDA-focused regulatory and...

Read more

U.S. Senator Roger Marshall Highlights Synexis as a Leader in Strengthening Public Health Following Facility Visit

July 16, 2026 12:40 PM

Following a recent visit to Synexis®, LLC, U.S. Senator Roger Marshall, M.D., praised the Kansas-based company's innovation, American-made touchless, continuous pathogen control technology and its positive impact on public health across sectors nationwide.During the visit, Senator Marshall met with Synexis leadership and team members, toured the company's operations, and learned more about patented DHP® technology - a continuous, proactive...

Read more

Imagene AI and Tel Aviv Sourasky University Medical Center (Ichilov) Build Clinical AI Infrastructure to Advance Precision Oncology and Biopharma R&D

July 16, 2026 9:00 AM

Imagene AI, a pioneer in multimodal AI for precision oncology, and Tel Aviv Sourasky University Medical Center (Ichilov), recognized among the top 100 hospitals globally in Newsweek's World's Best Hospitals 2026 ranking, today announced a strategic collaboration to build a clinical AI infrastructure designed to accelerate innovation in digital pathology, precision oncology, and biopharma research.By combining Tel Aviv Sourasky University Medical...

Read more

uBriGene Launches uVivo Lentiviral Vector Platform to Accelerate the Development of Next-Generation In Vivo CAR-T Therapies

July 16, 2026 7:00 AM

uBriGene Biosciences, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, today announced the launch of its patented uVivo™ Lentiviral Vector (LVV) Platform. uVivo™ LVV is a proven and targeted in vivo CAR-T platform that enables safer, more efficient, and commercially scalable in vivo CAR-T therapies.CAR-T cell therapy has transformed the treatment landscape for hematologic malignancies....

Read more